Lung Cancer Trial, Recruiting NCT06800586 Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06800586
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Patient groups:

  • Adults aged 18 or older who have been diagnosed with COPD (a lung disease) of any severity, are non-smokers (meaning they have smoked fewer than 100 cigarettes total in their lifetime and do not currently smoke), and are enrolled at the Pneumology Department in Bologna
  • Adults aged 18 or older who have been diagnosed with any type or stage of lung cancer, are non-smokers by the same definition, and are enrolled at the Medical Oncology Department in Bologna
  • Adults aged 18 or older who have been diagnosed with any type of leukemia (a blood cancer), are non-smokers by the same definition, and are enrolled at the Hematology Department in Foggia

Healthy volunteer groups:

  • Adults aged 18 or older who are non-smokers, have no personal history of COPD, solid tumours, or leukemia, and are employees of one of the participating hospitals (Bologna or Foggia)
  • All participants in every group must sign an informed consent form agreeing to take part

Who may not be able to join:

COPD patient group (Bologna):

  • People with a condition called alpha-1 antitrypsin deficiency (a genetic disorder affecting the lungs and liver)

Lung cancer patient group (Bologna):

  • People who have a previous or current diagnosis of other solid tumours, myelodysplastic syndromes, or myeloproliferative neoplasms (certain blood or bone marrow conditions)
  • People who have previously received or are currently receiving cancer treatment (anti-cancer drugs)

Leukemia patient group (Foggia):

  • People who have previously been diagnosed with solid tumours, myelodysplastic syndromes, or myeloproliferative neoplasms
  • People who have previously been treated with specific cancer-related medications, including alkylating agents, hydroxyurea, topoisomerase II inhibitors, or lenalidomide
  • People with certain pre-existing genetic conditions, including Fanconi anaemia, ataxia-telangiectasia, Down syndrome, xeroderma pigmentosum, or Li-Fraumeni syndrome
  • People with an active infection of HIV, human T-lymphotropic virus (types 1 or 2), or Epstein-Barr virus

Healthy volunteer groups (all sites):

  • Employees who work specifically within the same department running the trial at their respective hospital are not eligible to join as healthy volunteers at that department

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Stefano Nava, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phone: +39 0512143253

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Registry
ClinicalTrials.gov
Start date
15 September 2025
Est. completion
1 July 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Identification of pollutants in biological samples; Identification of pollutants in biological samples; Identification of pollutants in biological samples; Identification of pollutants in biological samples; Identification of pollutants in biological samples; Identification of pollutants in biological samples

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov